Posted on: Mon, 06 Dec 2010 09:15:00 EST
HOUSTON, Dec 06, 2010 (BUSINESS WIRE) --
Emerging Healthcare Solutions, Inc. (PinkSheets: EHSI
PowerRating) announced today that its newly acquired biotechnology division Celulas Genetica seeks to contract a Chinese firm to test a new stem-cell treatment for liver disease.
Last week, Celulas Genetica purchased a license to develop and market the revolutionary Rutherford Procedure, a groundbreaking organ regeneration treatment intended to utilize proton-beam technology to destroy diseased organ tissue for regeneration using adult stem cells. Celulas Genetica licensed the procedure from a Chinese firm, BBFITCL, and views the emerging Asian superpower as the ideal locale to test and develop its potential new treatment for liver disease.
"China has pushed hard for years to become a world leader in the fields of stem cell research and regenerative medicine," said EHSI President and CEO Cindy Morrissey. "The scientific and medical resources needed to test the Rutherford Procedure are both abundant and affordable in China, and Celulas Genetica is currently exploring the possibility of working with a proton therapy facility there to develop this new treatment for liver disease."
Morrissey said she plans to travel to China soon to meet with Chinese stem-cell researchers and potentially help open a Celulas Genetica business office there. Extending its reach into the R&D hotbed of China would build on EHSI's rapidly expanding global footprint--Celulas Genetica is headquartered in Panama, and Morrissey opened EHSI business offices in Poland and Germany last month.
"Liver disease is a truly global affliction," Morrissey said. "It requires a global solution. Working together with scientists and doctors in Panama, China and elsewhere, we believe we can develop the Rutherford Procedure into an effective, minimally invasive treatment for liver disease that will not require transplants."
Last week, EHSI announced its acquisition of a Rotary Cell Culture System, or bioreactor, developed using revolutionary NASA research in the field of microgravity. Cell cultures, including stem cells, grown inside the bioreactor look and function much closer to human cells grown within the body than cell cultures grown in Petri dishes. During the Rutherford Procedure, proton therapy will be used to destroy scar-tissue cells in the liver using high-energy proton beams, a non-invasive treatment proven to minimize damage to healthy tissues and to eliminate the side effects (including nausea) of traditional radiation therapy.
As the scar tissue is systematically destroyed by the proton therapy, a catheter will deliver the patient's own cultured stem cells directly to his or her liver through the bloodstream. As more and more diseased tissue is destroyed, these cultured stem cells could help regenerate the patient's damaged, cirrhotic liver into a healthy, functioning organ once more.
EHSI invests in technology developed to compete in the stem-cell research industry alongside Dendreon Corp. (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Celgene Corp. (NASDAQ: CELG) and Biogen Idec Inc. (NASDAQ: BIIB).
About Emerging Healthcare Solutions, Inc.
Emerging Healthcare Solutions, Inc. invests in and participates in the profits of emerging breakthrough medical technologies. The Company believes the secret of leveraging future value for its shareholders is the proper timing of its investment in promising new medical technologies. EHSI aims to capture future profits of promising new medical technologies by investing in these technologies at the inflection point of product development. We believe this model will deliver long-term positive results for our investors.
For more information, please visit http://www.emerginghealthcaresolutionsinc.com/.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.
SOURCE: Emerging Healthcare Solutions, Inc.
Emerging Healthcare Solutions, Inc.
Cindy Morrissey, 713-821-1486
President and CEO
Source
No comments:
Post a Comment